(10.05.2019, 15:51)Guhu schrieb: ... .Halte auch JNJ aus den Gründen, Pharma macht da nur einen Bruchteil aus.
DAS nun wieder auch nicht!
- Pharmaceuticals (50% of sales, 61% of pretax profits): dozens of patented drugs and vaccines to treat oncology, cardiovascular, immunological, neurological, and infectious diseases, and diabetes. Remicade, a treatment for a number of immune-mediated inflammatory diseases, is Johnson & Johnson’s largest drug and accounted for 6.5% of company-wide revenue in 2018.
- Medical Devices (33% of sales, 29% of pretax profits): surgical, orthopedic, endomechanical (i.e. hip replacements), and sterilization equipment.
- Consumer Products (17% of sales, 10% of pretax profits): over-the-counter consumer medical and beauty products including more than a dozen mega-brands (over $1 billion in annual sales) such as Johnson & Johnson, Neutrogena, Splenda, Listerine, Tylenol, Motrin, Sudafed, Band-Aid, Aveeno, Pepcid, Benadryl, and Zyrtec.
https://2.simplysafedividends.com/trading_items/2623227
(variierende Zahlen, aber die message ist eindeutig, dass Pharma kein Bruchteil darstellt) Aber korrekt, Medikamente werden selbstredend auch an Krankenhäuser verkauft - logo!
